Sadiya Al Menhali and Fatme Al Anouti
Asthma is defined as the chronic inflammation of the large airways that is characterized by reversible airflow obstruction and airway hyper-responsiveness. On the other hand, Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammation that is marked by progressive and irreversible airflow obstruction. Both conditions are manifested by symptoms of wheezing, coughing, and shortness of breath. Similarity in symptoms between these two conditions could lead to misdiagnosis and mistreatment. Although inflammation is present in both conditions, there are some marked differences. The main difference is that inflammation in asthma is an IgE mediated and involves the release of histamine while it is absent in the case of COPD. There is now a new trend for measuring the content of exhaled nitric oxide as a marker for assessing airway inflammation and especially for asthma diagnosis and monitoring. This study aimed at utilizing biomarkers to differentiate between the different types of respiratory inflammations. In this study, 23 patients with asthma, 20 with allergic rhinitis, 10 with COPD, and 17 healthy controls were recruited into the study at a local hospital clinic and assessed based on the level of their exhaled nitric oxide (eNO), serum specific IgE antibodies, and relative blood eosinophilia count. The results demonstrated that the many asthmatics (74%) had high eNO levels, while only 25% of patients with allergic rhinitis, 10% of those with COPD, and 6% of the healthy individuals similarly had elevated eNO levels. The results confirmed the fact that exhaled nitric oxide could be an effective parameter for differentiating asthma from other allergic diseases (e.g. allergic rhinitis) and other respiratory inflammations (COPD).
இந்தக் கட்டுரையைப் பகிரவும்
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 